机构概况
机构简介   现任领导
历任领导   学术委员会
学位委员会   组织机构
两院院士   历史沿革
园区风貌   历年年报
人才招聘  
研究队伍
院士专家
研究组长
万人计划
杰出青年
博士后流动站
人才招聘
 您现在的位置:首页 > 研究队伍
研究队伍
姓 名:
 黄永焯
性 别:
 男
职 称:
 研究员
学 历:
 博士
电 话:
 +86-21-20231000-1401
传 真:
 
电子邮件:
 yzhuang@mail.shcnc.ac.cn
个人主页:
黄永焯课题组">黄永焯课题组
通讯地址:
 上海市浦东新区海科路501号 201203
简历:

教育经历
2002.09 - 2005.07 浙江大学药学院
1999.09 - 2002.07 广州中医药大学临床药理研究所
1995.09 - 1999.07 广州中医药大学中药学院

工作经历
2010.07 - 至今    中国科学院上海药物研究所
2008.09 - 2010.06 University of Michigan, Senior Research Fellow
2005.11 - 2008.08 University of Michigan, Research Fellow


研究方向:
1.靶向给药系统
2.透皮给药
3.难溶性药物给药技术

专家类别:
研究员

职务:
中科院上海药物所研究组长;博士生导师

科研成果:

采用先进药物递送技术提高体内药物输送效率,并对其转运特性及机制进行了研究,着重考察了在耐药肿瘤治疗的应用。多药耐药已成为了肿瘤治疗最大的障碍之一,本课题组的研究聚焦于耐药肿瘤治疗的这一关键科学问题,通过靶向调控肿瘤微环境的递药策略及治疗策略,致力于研究肿瘤相关巨噬细胞调控与肿瘤耐药(化疗耐药、分子靶向治疗耐药及免疫耐药)。


承担科研项目情况:

1.国家自然科学基金重大研究计划(91029743,培育项目)(主持)

2.国家自然科学基金面上项目(81172996)(主持)

3.国家自然科学基金面上项目(81373357)(主持)

4.国家自然科学基金优秀青年基金(2014年)

5.国家自然科学基金面上项目(81673382)(主持)

6.973课题(2014CB931902)(主持)

7.973课题(2013CB932503)(参与)

8.国家自然科学基金创新群体(81521005)(参与)


社会任职:

1. 上海市药学会药剂学专业委员会委员
2. 世中联中药药理专业委员会委员
3. 世中联经皮给药专业委员会常务理事
4. 中国抗癌协会纳米肿瘤学常务委员
5. 全国卫生产业企业管理协会精准医疗分会理事
6. 中药新药与临床药理编委
7. 药学学报(中英文版)青年编委
8. 中国现代应用药学编委
9. Heliyon 编委


获奖及荣誉:

2010 中国科学院百人计划
2011 上海市浦江人才计划
2013 中国药学会-赛诺菲青年生物药物奖
2014 国家自然科学基金优秀青年基金
2015 “中国科学院百人计划”终期评估优秀
2016 中和多肽青年科学家奖
2017 中国科学院特聘研究员计划
2017 科技部中青年创新领军人才


代表论著:

近期代表论文(2011至今)  

1.Sun XY*, Zeng LH, Huang YZ*. Transcutaneous Delivery of DNA/mRNA for Cancer Therapeutic Vaccination. Journal of Gene Medicine 2019, accepted
2.Wang HR, Tang YS, Fang YF, Zhang M, Wang HY, He ZD, Wang B, Xu Q, and Huang YZ*. Reprogramming Tumor Immune Microenvironment (TIME) and 2 Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. Nano Letters 2019, DOI: 10.1021/acs.nanolett.9b00021
3.Zhang WY, Kang XJ, Yuan B, Wang HY, Zhang T, Shi MJ, Zheng ZN, Zhang YH, Peng CY, Fan XM, Shen YQ, Huang YZ*. Nano-structural effects on gene transfection: large, botryoid-shaped nanoparticles enhance DNA delivery via macropinocytosis and effective dissociation, Theranostics 2019, 9(6):1580-98
4.Chang Y, Yao S, Chen YF, Huang JJ, Wu AH, Zhang M, Xu Fan, Li F ang Huang YZ*. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy. Nanoscale 2019, 11, 611-621.
5.Jin HY, He Y, Zhao PF, Hu Y*, Tao J, Chen J, Huang YZ*. Targeting lipid metabolism to overcome EMTassociated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 2019, 9(1): 265-278 (Front cover).
6.Chen W, Yang W, Chen PY, Huang YZ*, Feng L*. Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers. ACS Appl. Mater. Interfaces 2018, 10, 48, 41118-41128
7.Zhao PF, Wang HY, Wu AH, Rao YF, and Huang YZ*. Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery. Chembiochem 2018, 19(17): 1796-1805.
8.Yin WM, Yu XL, Kang XJ, Zhao YG, Zhao PF, Jin HY, Fu XH, Wan YK*, Peng CY, and Huang YZ*. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. Small 2018, 14(47): 1802372.
9.Mo XP, Zheng ZN, He Y, Zhong HH, Kang XJ, Shi MJ, Liu TB, Jiao Z, Huang YZ*. Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. Journal of Controlled Release 2018, 287: 12-23.
10.Kang XJ, Zheng ZN, Liu ZH, Wang HY, Zhao YG, Zhang WY, Shi MJ, He Y, Cao Y, Xu Q,* Peng CY; Huang YZ*. Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis. Molecular Pharmaceutics 2018, 15, 1618?1626.
11.Zhao PF, Wang YH, Kang XJ, Wu AH, Yin WM, Tang YS, Wang JY, Zhang M, Duan Y and Huang YZ*. Dual-Targeting Biomimetic Delivery for Antiglioma via Remodeling Tumor Microenvironment and Directing Macrophage-Mediated Immunotherapy. Chemical Science 2018, 2674–2689 (Back front cover)
12.Xu F, Zhong HH, Chang Y, Li DD, Jin HY, Zhang M, Wang HY, Jiang C, Shen YQ, Huang YZ*. Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuliresponsive self-assembling nanocomposites. Biomaterials 2018, 158:56-73
13.Li DD, Zhang M, Xu F, Chen YZ, Chen BF, Chang Y, Zhong HH, Jin HY, Huang YZ*. Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation. Acta Pharmaceutica Sinica B 2018, 8(1): 74-84 (Back front cover)
14.Chen YZ, Zhang M, Min KA, Wang HY, Shin MC*, Li F, Yang V, Huang YZ*. Improved Protein Toxin Delivery Based on ATTEMPTS Systems. Current Drug Targets 2018, 19(4): 380-392
15.He Y, Li F*, Huang YZ*. Smart Cell-Penetrating Peptide-Based Techniques for Intracellular Delivery of Therapeutic Macromolecules. Adv Protein Chem Struct Biol. 2018;112:183-220
16.Peng HG, Chen BF, Huang W, Tang YB, Jiang YF, Zhang WY, Huang YZ*. Reprogramming Tumor-Associated Macrophages to Reverse EGFR(T790M) Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. Nano Letters 2017, 17(12): 7684-90
17.Zhao PF, Yin WM, Wu AH, Tang YS, Wang JY, Pan ZZ, Lin TT, Zhang M, Chen BF, Duan Y, Huang YZ*. Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy. Advanced Functional Materials 2017, 27(44): 1700403 (Front Cover)
18.Chen YZ, Zhang M, Jin HY, Li DD, Xu F, Wu AH, Wang JY, Huang YZ*. Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery. Theranostics 2017, 7(14): 3489-503
19.Xu JJ, Xu BH, Tao J, Yang YX, Hu Y*, Huang YZ*. Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel. Small 2017, 13(28): 1700666
20.Chen YZ, Zhang M, Jin HY, Tang YS, Wang HY, Xu Q, Li YP, Li F, Huang YZ*. Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature. Biomaterials 2017, 116: 57-68
21.Tang YS, Liang JM, Wu AH, Chen YZ, Zhao PF, Lin TT, Zhang M, Xu Q*, Wang JM*, Huang YZ*. Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis. ACS Applied Materials & Interfaces 2017, 9(32): 26648-64
22.Pan ZZ, Kang XJ, Zeng YE, Zhang WY, Peng HG, Wang JY, Huang W, Wang HY*, Shen YQ, Huang YZ*. A mannosylated PEI–CPP hybrid for TRAIL gene targeting delivery for colorectal cancer therapy. Polymer Chemistry 2017, 8(35): 5275-85 (Front Cover)
23.Chen YZ, Zhang M, Jin HY, Tang YS, Wu AH, Xu Q, Huang YZ*. Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance. Molecular Pharmaceutics 2017, 14(5): 1429-38
24.Tan J, Wang HY, Xu F, Chen YZ, Zhang M, Peng HG, Sun X*, Shen YQ, Huang YZ*. Poly-γ-glutamic acid-based GGT-targeting and surface camouflage strategy for improving cervical cancer gene therapy. Journal of Materials Chemistry B 2017, 5:1315-1327
25.Kan XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q*, Huang YZ*. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacologica Sinica 2017, 38(6): 885-96 (Serving as Co-Guest Editors for the featured issue)
26.Zhang M, Liu E, Cui Y, Huang YZ*. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biology & Medicine 2017, 14(3): 212-27
27.Wang HY, Moon C, Shin MC, Wang YP, He HN, Yang V*, Huang YZ*. Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. Nanotheranostics 2017, 1(1): 114-30
28.Lin TT, Zhao PF, Jiang YF, Tang YS, Jin HY, Pan ZZ, He HN, Yang V, Huang YZ*. Blood–Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano 2016, 10:9999-10012
29.Cui YN, Zhang M, Zeng F, Jin HY, Xu Q, Huang YZ*. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Applied Materials & Interfaces 2016, 8: 32159-32169
30.Lin TT, Liu EG, He HN, Shin MC, Moon C, Yang V*, Huang YZ*. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharmaceutica Sinica B 2016, 6: 352–358 (Back front cover)
31.Pan ZZ, Wang HY, Zhang M, Lin TT, Zhang WY, Zhao PF, Tang YS, Xiong Y, Zeng YE* and Huang YZ*. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacologica Sinica 2016, 37: 1110–1120 (Editor choice)
32.Wang HY, Jiang YF, Peng HG, Chen YZ, Zhu PZ, Huang YZ*. Recent Progress in microRNA Delivery for Cancer Therapy by Non-viral Synthetic Vectors. Advanced Drug Delivery Reviews 2015, 81:142-60
33.Wang YP, Lin TT, Zhang WY, Jiang YF, Jin HY, Yang VC, Chen Y and Huang YZ*. A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging. Theranostics 2015, 5:787-795
34.Hu Y, Xu BH, Xu JJ, Shou D, Liu EG, Gao JQ, Liang WQ, and Huang YZ*, Microneedle-assisted Dendritic Cell-targeted Nanoparticles for Transcutaneous DNA Immunization. Polymer Chemistry 2015, 6: 373-379 (Front Cover)
35.Liang JM, Zeng F, Zhang M, Pan ZZ, Chen YZ, Zeng YE, Xu Y, Xu Q*, Huang YZ*. Green synthesis of hyaluronic acid-based silver nanoparticles and their enhanced delivery to CD44+ cancer cells. RSC Advances 2015,5, 43733-43740
36.Jiang YF, Lu JY, Wang YP, Zeng F, Wang HY, Peng HG, Huang M, Jiang HL, Luo C* and Huang YZ*, Molecular-Dynamics-Simulation-Driven Design of a Protease-Responsive Probe for In Vivo Tumor Imaging. Advanced Materials 2014, 26: 8174-8
37.Wang YP, Jiang YF, Zhang M, Tan J, Liang JM, Wang HX, Li YP, He HN, Yang V*, Huang YZ*. Protease-activatable Hybrid Nanoprobe for Tumor Imaging. Advanced Functional Materials 2014, 24: 5443-53.
38.Wang HX, Zhao YX, Wang HY, Gong JB, He HN, Yang V*, Huang YZ*. Low-Molecular-Weight Protamine-Modified PLGA Nanoparticles for Overcoming Drug-Resistant Breast Cancer. Journal of Controlled Release 2014, 192: 47–56
39.Wang HY, Wang HX, Liang JM, Jiang YF, Guo QQ, Peng HG, Xu Q, Huang YZ*. Cell-penetrating Apoptotic Peptide/p53 DNA Nanocomplex as Adjuvant Therapy for Drug-resistant Breast Cancer. Molecular Pharmaceutics 2014, 11:3352-60
40.Wang HY, Li F*, Du C, Wang HX, Mahato RI, Huang YZ*. Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. Molecular Pharmaceutics 2014, 11: 2600-11 (Serving as Co-Guest Editors for the featured issue)
41.Tan J, Cheong HS, Park YS, Kim HG, Zhang M, Moon C* and Huang YZ*. Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs. Current Pharmaceutical Biotechnology. 2014, 15(3):231-9 (Serving as Guest Editor for the featured issue)
42.Wang Z, Chen YZ, Liu EG, Gong JB, Shin MC, Huang YZ*. CPP-mediated Protein Delivery in a Noncovalent Form: Proof-of-Concept for Percutaneous and Intranasal Delivery. Protein Peptide Letters 2014, 21:1129-36.
43.Huang YZ*, Jiang YF, Wang HY, Wang JX, Shin MC, Byun Y, He HN, Liang YQ, and Yang V*. Curb challenges of the "Trojan Horse" approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Advanced Drug Delivery Reviews 2013, 65: 1299-315.
44.Wang HY, Guo QQ, Jiang YF, Liu EG, Zhao YX, Wang HX, Li YP*, Huang YZ*. Co-delivery of Cell-permeable Chimeric Apoptosis AVPIR8 Peptide/p53 DNA for Cocktail Therapy. Advanced Functional Materials 2013, 23: 6068-75.
45.Guo QQ, Wang HY, Zhao YX, Liu EG, Wang HX, Hua HY, Huang YZ*. Cell-penetrating Albumin Conjugates for Enhanced Doxorubicin Delivery. Polymer Chemistry 2013, 4: 4584-4587. (Highlighted as “Paper of the Week”)
46.Wang Y, Liu EG, Sun XY, Huang PY, Long H, Wang H, Yu X, Zheng CH, Huang YZ*. Pluronic L61 as a long-circulating modifier for enhanced liposomal delivery of cancer drugs. Polymer Chemistry 2013, 4: 2958-2962.
47.Yan L, Wang HY, Jiang YF, Liu JH, Wang Z, Yang YX, Huang SW, Huang YZ*. Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery. Macromolecular Research 2013, 21: 435-441.
48.Liu JH, Zhao YX, Guo QQ, Wang Z, Wang HY, Yang YX, Huang YZ*. TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials 2012, 33: 6155-61.
49.Yang YX, Jiang YF, Wang Z, Liu JH, Yan L, Ye JX, Huang YZ*. Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery. Journal of Materials Chemistry 2012, 22: 10029-34.
50.Wang S, Wang H, Liang W*, Huang YZ*. An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs. Nanoscale Research Letters 2012, 7:219
51.Yang YX, Gao Y, Chen L, Huang YZ*, and Li YP*. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles. International Journal of Pharmaceutics 2011, 405:188-195
52.Dong SY, Wang S, Zheng CH, Liang W*, and Huang YZ*. An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics. Soft Matter 2011, 7:5873-5878

A full publication list is available via Google Scholar. https://scholar.google.com/citations?user=Z-yoe34AAAAJ

Book Chapter:
1.Liu EG, Zhang M, Huang YZ*. Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials. Chapter 1 in Biomedical Nanomaterials.  2016 Wiley-VCH
2.Mo XP, Liu EG, Huang YZ*. The intra-brain distribution of brain targeting delivery systems. Chapter in Brain Targeted Drug Delivery System 2018 Elsevier